- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.08. | Annexin Pharmaceuticals AB: Annexin receives approval for Phase 2a study in diabetic retinopathy and RVO | 87 | GlobeNewswire (Europe) | Annexin Pharmaceuticals AB has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to start a clinical Proof of Concept phase 2a study with the drug candidate ANXV... ► Artikel lesen | |
| 28.05. | XFRA NEW INSTRUMENTS AVAILABLE ON 28.05.2025 | 1.037 | Xetra Newsboard | The following instruments on XETRA do have their first trading 28.05.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 28.05.2025
Aktien
1 CNE100006XS6 Jiangsu Hengrui Pharmaceuticals... ► Artikel lesen | |
| 27.05. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 27.05.2025 | 582 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 27.05.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 27.05.2025ISIN NameCA42841L1085 HI-VIEW... ► Artikel lesen | |
| 27.05. | XFRA ISIN CHANGE | 564 | Xetra Newsboard | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenCA82888R1055 Simply Better Brands Corp. 27.05.2025 CA89778A1003 Trubar Inc. 28.05.2025 Tausch 1:1SE0009664154 Annexin... ► Artikel lesen | |
| 27.05. | XFRA CAPITAL ADJUSTMENT INFORMATION - 27.05.2025 | 613 | Xetra Newsboard | Das Instrument 6RJ US7731221062 ROCKET LAB USA A DL-,0001 EQUITY wird ex Kapitalmassnahme gehandelt am 27.05.2025 The instrument 6RJ US7731221062 ROCKET LAB USA A DL-,0001 EQUITY is traded ex capital... ► Artikel lesen | |
| ANNEXIN PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 26.05. | Reverse Split and Change of ISIN for Annexin Pharmaceuticals AB | 445 | GlobeNewswire | Referring to the press release from Annexin Pharmaceuticals AB's on 21 May, the company will carry out a reverse stock split in relations 1:100. The share will be traded under new ISIN code with... ► Artikel lesen | |
| 03.03. | XFRA CAPITAL ADJUSTMENT INFORMATION - 03.03.2025 | 475 | Xetra Newsboard | Das Instrument MBG DE0007100000 MERCEDES-BENZ GRP NA O.N. EQUITY wird ex Kapitalmassnahme gehandelt am 03.03.2025 The instrument MBG DE0007100000 MERCEDES-BENZ GRP NA O.N. EQUITY is traded ex capital... ► Artikel lesen | |
| 06.02. | Annexin Pharmaceuticals AB: Annexin resolves on a rights issue of approximately SEK 50 million, secured to approximately 80 percent, subject to approval by the Extraordinary General Meeting | 339 | GlobeNewswire (Europe) | NOT INTENDED FOR DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, RUSSIA, SINGAPORE, SOUTH KOREA, SOUTH AFRICA OR NEW... ► Artikel lesen |
8 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 96,05 | +0,05 % | BioNTech erreicht Phase-3-Erfolg bei Brustkrebsstudie mit BNT323 | BioNTech hat gemeinsam mit DualityBio einen wichtigen Studienerfolg erzielt: In einer von DualityBio in China durchgeführten Phase-3-Studie erreichte der Antikörper-Wirkstoff-Kandidat Trastuzumab Pamirtecan... ► Artikel lesen | |
| QIAGEN | 40,390 | +0,44 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Dies schrieb Analyst Tycho Peterson in seinem am Freitag... ► Artikel lesen | |
| NUVALENT | 80,89 | +1,53 % | Nuvalent, Inc.: Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results | Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of... ► Artikel lesen | |
| DYNE THERAPEUTICS | 14,220 | +7,40 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) | - Data from the DELIVER registrational expansion cohort is expected in late 2025, with a potential BLA submission for U.S. accelerated approval anticipated in early 2026 - WALTHAM, Mass., Aug.... ► Artikel lesen | |
| EVOTEC | 5,856 | +2,70 % | INSIDERALARM bei Evotec! Valneva mit neuem KURSZIEL! Vidac Pharma Aktie bald mit neuem ALLZEITHOCH? | Endlich! Bei Evotec sorgen Insider für ein wichtiges Signal. Die Aktie reagiert zwar noch nicht, aber mittelfristig könnte sich dies als Kaufsignal herausstellen. Derzeit herrscht noch Skepsis. Bullish... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,610 | +1,99 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update | SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 50,38 | +3,81 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
| BEAM THERAPEUTICS | 20,890 | +12,68 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 25,980 | +9,16 % | Summit Therapeutics stock maintains Buy rating at H.C. Wainwright on ivonescimab progress | ||
| MINERALYS THERAPEUTICS | 34,750 | +4,92 % | Mineralys reports positive subgroup data for hypertension drug | ||
| VERA THERAPEUTICS | 24,220 | +10,59 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| CG ONCOLOGY | 33,105 | +7,00 % | CG Oncology Inc.: CG Oncology Completes Enrollment in PIVOT-006 | - Rapid enrollment underscores high unmet need in intermediate-risk non-muscle invasive bladder cancer (NMIBC) -- One of the largest randomized phase 3 studies in this patient population will encompass... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 59,42 | -0,50 % | MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update | Phase 3 VELA program in hidradenitis suppurativa (HS) on track for an expected primary endpoint readout around September 2025 and an expected submission of a Biologic License Application (BLA) in the... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 10,090 | -5,61 % | Roth/MKM initiates ARS Pharmaceuticals stock with Buy rating on neffy potential | ||
| ARCUTIS BIOTHERAPEUTICS | 17,200 | +6,11 % | Arcutis Biotherapeutics, Inc.: Arcutis Submits Supplemental New Drug Application for ZORYVE (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5 | If approved, ZORYVE cream would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children as young as 2, offering patients and caregivers an important alternative to... ► Artikel lesen |
Das Unternehmen ANNEXIN PHARMACEUTICALS AB kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 2,460 Euro und damit +3,36 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ANNEXIN PHARMACEUTICALS AB finden Sie auf Wallstreet Online.